EnPro Sets 2026 Outlook for 8%–12% Sales Growth as AST Recovery Skews to Second Half

Overview

• The company closed 2025 with 7.6% organic sales growth, $150 million in free cash flow, and Sealing Technologies margins above 32%.
• Management completed termination of the U.S. defined benefit pension plan, recording a non-cash settlement loss of $67.2 million.
• EnPro invested $280 million to acquire Alpha and Overlook, expanding into compositional analysis and life sciences capabilities.
• AST faces a $12 million revenue headwind from 2025 safety‑stock shipments, with margin expansion expected as prior $8 million in operating investments begin to leverage.
• Planned 2026 capital spending is about $50 million, with two‑thirds for growth and efficiency, as the outlook notes persistent market variability and higher corporate medical and incentive costs.